You are here: Home: LCU Think Tank 1 | 2006: Section1: Select publications

SELECT PUBLICATIONS

Auberger J et al. Targeted therapies in non-small cell lung cancer: Proven concepts and unfulfilled promises. Curr Cancer Drug Targets 2006;6(4):271-94. Abstract

Davila E et al. Phase II trial of oxaliplatin and gemcitabine with bevacizumab in first-line advanced non-small cell lung cancer (NSCLC). Proc ASCO 2006;Abstract 17009.

Dowlati A et al. Prospective correlative assessment of biomarkers in E4599 randomized phase II/III trial of carboplatin and paclitaxel ± bevacizumab in advanced non-small cell lung cancer (NSCLC). Proc ASCO 2006;Abstract 7027.

Fehrenbacher L et al. A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. Presentation. Proc ASCO 2006;Abstract 7062.

Gordon MS et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19(3):843-50;Abstract.

Sandler A. Bevacizumab and non-small cell lung cancer. Presentation. Lung Cancer Update Think Tank Meeting 2006. No abstract available

Sandler AB et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) trial — E4599. Presentation. Proc ASCO 2005;Abstract 4.

Shepherd FA et al; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353(2):123-32. Abstract

Table of Contents

Top of Page